Search hospitals

>

New Jersey

>

Camden

Cooper Hospital University Medical Center

Claim this profile

Camden, New Jersey 08103

Global Leader in Ovarian Cancer

Global Leader in Breast Cancer

Conducts research for Fallopian Tube Cancer

Conducts research for Stroke

Conducts research for Peritoneal Cancer

490 reported clinical trials

28 medical researchers

Photo of Cooper Hospital University Medical Center in CamdenPhoto of Cooper Hospital University Medical Center in Camden

Summary

Cooper Hospital University Medical Center is a medical facility located in Camden, New Jersey. This center is recognized for care of Ovarian Cancer, Breast Cancer, Fallopian Tube Cancer, Stroke, Peritoneal Cancer and other specialties. Cooper Hospital University Medical Center is involved with conducting 490 clinical trials across 636 conditions. There are 28 research doctors associated with this hospital, such as Christopher Jones, David P. Warshal, Jamin C. Morrison, and Gary Eastwick.

Area of expertise

1

Ovarian Cancer

Global Leader

Cooper Hospital University Medical Center has run 51 trials for Ovarian Cancer. Some of their research focus areas include:

BRCA1 positive
Stage II
Stage III
2

Breast Cancer

Global Leader

Cooper Hospital University Medical Center has run 34 trials for Breast Cancer. Some of their research focus areas include:

ER positive
HER2 positive
PR positive

Top PIs

Clinical Trials running at Cooper Hospital University Medical Center

Lung Cancer

Ovarian Cancer

Stroke

Prostate Cancer

Breast Cancer

Acute Myeloid Leukemia

Pancreatic Cancer

Pancreatic Carcinoma

Uterine Cancer

Kidney Cancer

Image of trial facility.

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.

Recruiting

2 awards

Phase 3

14 criteria

Image of trial facility.

Stereotactic Radiosurgery vs Whole-Brain Radiotherapy

for Brain Metastasis from Lung Cancer

This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.

Recruiting

2 awards

Phase 3

15 criteria

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Cooper Hospital University Medical Center?

Where is Cooper Hospital University Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does Cooper Hospital University Medical Center accept?

What awards or recognition has Cooper Hospital University Medical Center received?